Brokerages Set Medpace Holdings, Inc. (NASDAQ:MEDP) Target Price at $376.30

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned an average recommendation of “Hold” from the thirteen brokerages that are covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $376.30.

Several research firms recently commented on MEDP. Leerink Partners started coverage on Medpace in a research note on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective for the company. Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Finally, Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a research report on Monday, March 24th.

Medpace Stock Down 1.3 %

Shares of NASDAQ MEDP opened at $312.36 on Friday. The firm has a market cap of $9.52 billion, a price-to-earnings ratio of 24.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The company’s 50-day simple moving average is $335.90 and its 200-day simple moving average is $339.18. Medpace has a 52-week low of $302.01 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities research analysts anticipate that Medpace will post 12.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Medpace

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MEDP. Lindbrook Capital LLC increased its position in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares during the last quarter. HBK Sorce Advisory LLC increased its position in shares of Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company’s stock valued at $1,789,000 after acquiring an additional 29 shares during the last quarter. Assetmark Inc. increased its position in shares of Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company’s stock valued at $57,000 after acquiring an additional 29 shares during the last quarter. Proficio Capital Partners LLC raised its stake in shares of Medpace by 4.1% in the 4th quarter. Proficio Capital Partners LLC now owns 730 shares of the company’s stock valued at $243,000 after acquiring an additional 29 shares during the period. Finally, Schulhoff & Co. Inc. lifted its holdings in shares of Medpace by 1.2% in the 4th quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company’s stock worth $874,000 after acquiring an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.